Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209072 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTPTGS1KMT2AMEN1 | |
| SCHEMBL1353684 | 0.87 | NOS1 (0.39) | ALDH1A1MAPTPTGS1KMT2AMEN1 | |
| SCHEMBL5346485 | 0.81 | MEN1 (0.35) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL5409743 | 0.81 | NOS1 (0.36) | ALDH1A1MAPTPTGS1KMT2ANOS1 | |
| SCHEMBL16340968 | 0.81 | NOS1 (0.39) | ALDH1A1MAPTPTGS1KMT2ANOS1 | |
| SCHEMBL28113585 | 0.81 | NOS1 (0.36) | ALDH1A1MAPTPTGS1KMT2ANOS1 | |
| SCHEMBL3204138 | 0.79 | SLC7A5 (0.42) | ALDH1A1MAPTPTGS1KMT2AMEN1 | |
| SCHEMBL523836 | 0.79 | DGAT1 (0.41) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27549577 | 0.79 | NOS1 (0.35) | KMT2ANOS1NOS3NOS2LMNA | |
| SCHEMBL4106257 | 0.77 | KMT2A (0.39) | ALDH1A1MAPTPTGS1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021115188-A1 | HISTONE DEACETYLASE, AND PROTEASOME DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东大学 | 2021-06-17 | — | — | WO | claimed |
| CN-110950897-A | Histone deacetylase, protease double-target inhibitor, preparation method and application thereof | 山东大学 | 2020-04-03 | — | — | CN | claimed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024255806-A1 | PREPARATION AND USE OF HYDROGEL | 粤港澳大湾区精准医学研究院(广州) | 2024-12-19 | — | — | WO | disclosed |
| US-20240083922-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11833204-B2 | Visible light-activatable nanoparticles for cancer immunotherapy and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11566039-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220370611-A1 | VISIBLE LIGHT-ACTIVATABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-11-24 | — | — | US | disclosed |
| EP-3842430-B1 | SET8 LYSINE METHYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HAINAN YILING MEDICAL IND & DEVELOPMENT CO LTD (CN) | 2022-09-28 | — | — | EP | disclosed |
| WO-2000012587-A2 | POLYAMIDE CHAINS OF PRECISE LENGTH, METHODS TO MANUFACTURE THEM AND THEIR CONJUGATES | GRYPHON SCIENCES (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5994350-A | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; RESPIRATORY SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 1999-11-30 | — | — | US | disclosed |
| CN-1202886-A | 3-spiroindolin-2-one derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI CO (FR) | 1998-12-23 | — | — | CN | disclosed |
| EP-0873309-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1998-10-28 | — | — | EP | disclosed |
| US-5633270-A | Thiazolidine derivatives, preparation thereof and drugs containing samem | RHONE-POULENC RORER S.A. (FR) | 1997-05-27 | — | — | US | disclosed |
| WO-1997015556-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1997-05-01 | — | — | WO | disclosed |
| WO-1994018230-A1 | INHIBITION OF HIV REPLICATION BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5045540-A | Amide or urea compounds containing imidazole groups | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5041552-A | Treatment of hypertension, heart failure, glaucoma and hyperaldosteronism | WARNER-LAMBERT COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | ALDH1A1 2370/4885MAPT 3722/4885PTGS1 2992/4885 |
| US-20240083922-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | ALDH1A1 4093/4885MAPT 644/4885PTGS1 2574/4885 |
| US-11833204-B2 | Visible light-activatable nanoparticles for cancer immunotherapy and use thereof | CD47, PDCD1, TP53 | ALDH1A1 3091/4885MAPT 635/4885PTGS1 1612/4885 |
| US-20220370611-A1 | VISIBLE LIGHT-ACTIVATABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY AND USE THEREOF | CD47, PDCD1, TP53 | ALDH1A1 3091/4885MAPT 635/4885PTGS1 1612/4885 |
| US-11566039-B2 | Lincosamide antibiotics and uses thereof | NPEPPS, ASNS, LNPEP | ALDH1A1 2845/4885MAPT 2396/4885PTGS1 3910/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | ALDH1A1 4093/4885MAPT 644/4885PTGS1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.